Dissecting the roles of type 2 diabetes-associated variants and effector genes in islet endoplasmic reticulum stress response
Project Number5F30DK130582-04
Former Number1F30DK130582-01
Contact PI/Project LeaderBHUIYAN, REDWAN
Awardee OrganizationUNIVERSITY OF CONNECTICUT SCH OF MED/DNT
Description
Abstract Text
PROJECT SUMMARY
Type 2 Diabetes (T2D) is a complex disease caused by both genetic and environmental factors. Genome-wide
association studies (GWAS) have identified 403 association signals at 243 loci (T2D variants) that increase T2D
genetic risk. Functional (epi)genomic analyses strongly suggest that non-coding T2D variants alter transcriptional
regulation and target gene expression in pancreatic islets, but only ~20% of T2D variants elicit changes in islet
cis-regulatory element (CRE) use or gene expression under steady state conditions. Environmental factors such
as endoplasmic reticulum (ER) stress have been implicated in islet dysfunction. However, studies to date have
not assessed if or how T2D variants modulate the response of islets to ER stress. I hypothesize that these T2D
variants alter islet ER stress-responsive CRE use or activity and target gene expression to contribute to
islet β cell dysfunction or death in T2D. In my preliminary data analysis, I have identified ER stress-responsive
CREs that overlap 407 T2D variants in islets and connected these CREs to 22 putative target gene promoters
using islet promoter capture Hi-C maps. In Aim 1, I will comprehensively assess the effects of T2D variants on
the use or activity of ER stress-responsive CREs using chromatin accessibility quantitative trait locus (caQTL)
and massively parallel reporter assays (MPRA), respectively. In Aim 2, I will determine if the putative CRE-
targeted genes are required in human islet cells for their ER stress response and survival by altering their
expression using CRISPR/Cas9 epigenomic editing platforms. Successful completion of these Aims will yield a
functionally characterized set of T2D variants and a validated set of downstream 'T2D target genes’ that
modulate islet function and survival in response to a central (patho)physiologic stressor. More broadly, I
anticipate that the principles and framework I employ in this mechanistic variant-to-function project could be
applied to characterize the effects of T2D variants in the context of other environmental stressors and metabolic
tissues. Importantly, completion of this project will help me master current concepts and state-of-the-art
techniques in genetics and functional genomics and increase my scientific communication skills through
extensive opportunities to present and publish my studies. Finally, my position as an MD/PhD student at UConn
Health and The Jackson Laboratory for Genomic Medicine will not only allow me to be mentored in a world-
class, highly collaborative environment, but it will provide me with opportunities to continue honing my clinical
skills and gain specialized experience during and after my research phase. Fulfilling my training and development
plan will be a crucial step toward my future career as a physician-scientist studying the genetic and (epi)genomic
mechanisms of disease-associated variants in patients.
Public Health Relevance Statement
PROJECT NARRATIVE
Type 2 diabetes (T2D) is a complex genetic disease caused by genetic and environmental factors. Genome-
wide association studies have identified hundreds of small genome sequence changes—called DNA sequence
variants—that are associated with increased risk of developing T2D, but how these variants affect the ability of
pancreatic cells to respond to stress is unknown. This project will assess how T2D-associated variants impact
the ability of pancreatic cells to respond to stress related to the burdens of making and secreting insulin, and
the findings are expected to broadly enhance our understanding of how T2D-associated variants affect
sensitivity to other forms of cellular stress and promote T2D.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
022254226
UEI
H6D6JMXJXDE6
Project Start Date
15-March-2022
Project End Date
14-March-2026
Budget Start Date
15-March-2025
Budget End Date
14-March-2026
Project Funding Information for 2025
Total Funding
$53,974
Direct Costs
$53,974
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Diabetes and Digestive and Kidney Diseases
$53,974
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5F30DK130582-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F30DK130582-04
Patents
No Patents information available for 5F30DK130582-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F30DK130582-04
Clinical Studies
No Clinical Studies information available for 5F30DK130582-04
News and More
Related News Releases
No news release information available for 5F30DK130582-04
History
No Historical information available for 5F30DK130582-04
Similar Projects
No Similar Projects information available for 5F30DK130582-04